GlaxoSmithKline’s maintenance therapy Votrient delayed disease progression in patients with advanced epithelial ovarian cancer by an average of 5.6 months following front-line chemotherapy.
In a Phase III clinical trial, Votrient (pazopanib) – already approved for kidney cancer – reduced the risk of disease progression or death by 23%.
Go deeper with GlobalData
The median progression-free survival for women in the Votrient group was 17.9 months, compared to 12.3 months for those taking the placebo.
More than 90% of ovarian cancers are classified as "epithelial", and are believed to arise from the surface of the ovary.
About 70% of patients with the advanced form of the disease experience a relapse following surgery and chemotherapy, and need to resume aggressive treatments.
GSK head of Oncology R&D Dr Rafael Amado commented on the results; "Ovarian cancer is a leading cause of cancer deaths among women, so we were excited to collaborate with AGO and other cooperative groups in the search for new treatments."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"This study showed that treatment with Votrient following surgery and chemotherapy extended the time that these women lived without their disease progressing. We are planning to submit regulatory applications in 2013."
In the US, there a no drugs approved as maintenance therapies for patients who have undergone treatment for advanced ovarian cancer, but Roche’s Avastin (bevacizumab) is approved in Europe for that use.
In an independent study published today, Avastin was shown to extend the lives of women with advanced cervical cancer when combined with chemotherapy, compared to chemotherapy alone.
The risk of death for women with cervical cancer was reduced by 29%.
